Capricor Therapeutics, Inc. (CAPR) Key Statistics & Financial Ratios

Capricor Therapeutics, Inc. (CAPR) — Price $8.56 — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for Capricor Therapeutics, Inc. (CAPR). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine.

Stock Data

Price$8.56
Market Cap$492M
Enterprise Value$562.4M
Beta0.48
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio-3.49
Price / Book2.01
P/S0.00
EV/EBITDA0.48
EV/Sales0.00
EV/FCF-4.33
P/FCF-3.79
Earnings Yield-26.10%
FCF Yield-26.36%
Dividend Yield0.00%

Profitability

Gross Margin0.00%
EBIT Margin0.00%
EBITDA Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Return on Equity-56.60%
Return on Assets-35.10%
Return on Invested Capital-40.08%
Return on Capital Employed-40.25%

Financial Health

Current Ratio7.35
Quick Ratio7.35
Cash Ratio0.64
Debt / Equity0.37
Debt / Assets24.69%
Net Debt / EBITDA0.06
Interest Coverage-44.38

Per-Share Data

Revenue per share0.00
Book Value per share4.25
Cash per share4.11
FCF per share-2.24
Tangible Book Value per share4.25
Dividend per share0.00

Related companies: ACHV · ALLO · ARCT · CABA · EDIT · IMMP · LXEO

Explore sector: Healthcare · Biotechnology

More sections of CAPR: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks